BerGenBio ASA (BRRGF) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
BerGenBio ASA has reported progress in its focused approach to develop bemcentinib for first-line treatment in NSCLC patients with STK11 mutations, highlighting the completion of Phase 1b enrollment and ongoing progress of the Phase 2a study. The company has decided to discontinue its tilvestamab activities, while maintaining a healthy financial position with cash reserves of NOK 174.8 million. Investors can expect an interim analysis of the bemcentinib study in early 2025.
For further insights into BRRGF stock, check out TipRanks’ Stock Analysis page.
